TRIPLE NEGATIVE BREAST CANCER

This study aimed to check the safety of a two-drug combination (atezolizumab plus nab-paclitaxel) for people with a hard-to-treat, advanced form of breast cancer that had spread. It involved 184 participants whose cancer tested positive for a specific marker (PD-L1) and who had n…

This study tested whether adding an experimental drug called TJ004309 to an existing immunotherapy (atezolizumab) could help control advanced cancers that have stopped responding to standard treatments. It involved 25 patients with specific types of advanced solid tumors, includi…

This study tested whether a drug called crizotinib, used for some lung cancers, could help control advanced lobular breast cancer and certain other hard-to-treat cancers. For breast cancer patients, it was combined with a hormone-blocking drug called fulvestrant. The main goal wa…

This study tested a specific sequence of four chemotherapy drugs given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer, a type that doesn't respond to hormone therapies. The main goal was to see if this treatment could completely eliminate the i…

This study tested whether giving two preventive medications (loperamide for diarrhea and G-CSF for low white blood cells) alongside the cancer drug sacituzumab govitecan could reduce its common and severe side effects. It involved 50 adults with advanced triple-negative or lumina…

This study tested whether a specific lab test, called the RAD51-foci score, could predict which patients with advanced HER2-negative breast cancer would benefit most from the drug olaparib. It involved 65 patients, some with known genetic mutations and some without, to see if the…

This study tested a new combination of two drugs, NT-I7 and pembrolizumab, for people with advanced solid tumors that had returned or stopped responding to prior therapies. The main goals were to find a safe dose and see if the combination could shrink tumors in several hard-to-t…

This small, early-stage study tested the safety of an experimental immune-boosting treatment called IRX-2. It was given as an injection near the breast tumor before patients with early-stage breast cancer had their standard surgery or chemotherapy. The main goal was to see if the…

This first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) i…

This study tested the safety and effectiveness of combining two drugs, pembrolizumab and lenvatinib, in people with advanced solid tumors that had stopped responding to standard treatments. It involved 611 participants with cancers like triple-negative breast, ovarian, gastric, c…

This study tested a new imaging agent to see if it could better detect where aggressive triple negative breast cancer has spread in the body. Researchers gave 12 patients with this cancer a new radioactive tracer and compared the scan results to a standard imaging method. The goa…

This study tested whether adding a breast MRI scan to the standard pre-surgery imaging (mammogram and ultrasound) helps doctors plan better surgery for women with early-stage breast cancer. It aimed to see if the extra scan leads to fewer cancer recurrences, fewer repeat surgerie…

This study aimed to understand if the types of bacteria in a person's gut and tumor are linked to how well they respond to standard chemotherapy for triple-negative breast cancer. Researchers followed 49 newly diagnosed patients, collecting stool, blood, and tumor samples before,…

This study aimed to create a communication tool to help doctors and patients have better conversations when cancer treatments stop working. Researchers interviewed 128 people, including cancer patients, parents of children with cancer, and healthcare professionals, to understand …

This study aimed to find a better way to choose chemotherapy for patients with triple-negative breast cancer before surgery. Researchers tested if a specific biomarker (called HRD score) from a tumor sample could predict whether a patient would respond better to the drug cisplati…